Document:

Exhibit 10.52

 

AMENDMENT #1

 

THIS
AMENDMENT #1 (the “Amendment”) to the Warrant (as defined below), is entered into by and between Bioxytran, Inc., a
Nevada corporation (the “Company”), and Auctus Fund, LLC, a Delaware limited liability company (the “Holder”)
(collectively the “Parties”).

 

BACKGROUND

 

A. The
Company and Holder entered into a securities purchase agreement on October 24, 2018 (the “SPA”), pursuant to which
the Company issued that certain convertible promissory note in the principal amount of $250,000.00 to the Holder (the “Note”).

 

B. The
Company issued that certain common stock purchase warrant to the Holder pursuant to the SPA, for the purchase of 208,333 shares
of the Company’s common stock, on October 24, 2018 (the “Warrant”), subject to anti-dilution protection as provided
therein.

 

NOW THEREFORE, the Parties agree as follows:

 

1. Notwithstanding
anything to the contrary contained in the Warrant, SPA, or Note, the remainder of the Warrant shall be extinguished in full once
(i) the Holder exercises a portion of the Warrant for an aggregate of 375,000 shares of the Company’s common stock (the “Shares”)
and (ii) the Company delivers the Shares without any restrictive legend to the Holder’s brokerage account via DWAC pursuant
to the original terms of the Warrant.

 

2. Once
the Shares are delivered to the Holder without any restrictive legend, the Holder shall direct the Company’s transfer agent
to release the Holder’s remaining share reservation with respect to the Note and Warrant.

 

3. The
issuance of the Shares will not trigger any default, penalty, or anti-dilution provision in the Note since the Company has repaid
the balance owed under the Note prior to the date of this Amendment.

 

4. The Holder’s
sale of the Shares during the calendar month of March 2020 shall be limited to 125,000 of the Shares.

 

5.
The Holder’s sale of the Shares during the calendar month of April 2020 shall be limited to 125,000 of the Shares.

 

6.
The Holder’s sale of the Shares during the calendar month of May 2020 shall be limited to 125,000 of the Shares.

 

7. This
Amendment shall be deemed part of, but shall take precedence over and supersede any provisions to the contrary contained in the
Warrant.

 

[signature page to
follow]

 

    1

     

    

 

IN WITNESS WHEREOF, the parties hereto have executed
this Amendment as of March 11, 2020.

 

BIOXYTRAN, INC.

 

	By:	 	 
	 	Name:  	DAVID PLATT	 
	 	Title: 	CHIEF EXECUTIVE OFFICER	 

 

AUCTUS FUND, LLC

 

	By:	 	 
	 	Name:  	LOU POSNER	 
	 	Title: 	MANAGING DIRECTOR	 

 

 

2Exhibit 10.53

 

AMENDMENT #1

 

THIS
AMENDMENT #1 (the “Amendment”) to the Warrant (as defined below), is entered into by and between Bioxytran, Inc., a
Nevada corporation (the “Company”), and Auctus Fund, LLC, a Delaware limited liability company (the “Holder”)
(collectively the “Parties”).

 

BACKGROUND

 

A. The
Company and Holder entered into a securities purchase agreement on February 25, 2019 (the “SPA”), pursuant to which
the Company issued that certain convertible promissory note in the principal amount of $250,000.00 to the Holder (the “Note”).

 

B. The
Company issued that certain common stock purchase warrant to the Holder pursuant to the SPA, for the purchase of 208,333 shares
of the Company’s common stock, on February 25, 2019 (the “Warrant”), subject to anti-dilution protection as provided
therein.

 

NOW THEREFORE, the Parties agree as follows:

 

1. Notwithstanding
anything to the contrary contained in the Warrant, SPA, or Note, the remainder of the Warrant shall be extinguished in full once
(i) the Holder exercises a portion of the Warrant for an aggregate of 375,000 shares of the Company’s common stock (the “Shares”)
and (ii) the Company delivers the Shares without any restrictive legend to the Holder’s brokerage account via DWAC pursuant
to the original terms of the Warrant.

 

2. Once
the Shares are delivered to the Holder without any restrictive legend, the Holder shall direct the Company’s transfer agent
to release the Holder’s remaining share reservation with respect to the Note and Warrant.

 

3. The
issuance of the Shares will not trigger any default, penalty, or anti-dilution provision in the Note since the Company has repaid
the balance owed under the Note prior to the date of this Amendment.

 

4.
The Holder’s sale of the Shares during the calendar month of March 2020 shall be limited to 125,000 of the Shares.

 

5.
The Holder’s sale of the Shares during the calendar month of April 2020 shall be limited to 125,000 of the Shares.

 

6.
The Holder’s sale of the Shares during the calendar month of May 2020 shall be limited to 125,000 of the Shares.

 

7. This
Amendment shall be deemed part of, but shall take precedence over and supersede any provisions to the contrary contained in the
Warrant.

 

[signature page to
follow]

 

    1

     

    

 

IN WITNESS WHEREOF, the parties hereto have executed
this Amendment as of March 11, 2020.

 

BIOXYTRAN, INC.

 

	By:	 	 
	 	Name:  	DAVID PLATT	 
	 	Title: 	CHIEF EXECUTIVE OFFICER	 

 

AUCTUS FUND, LLC

  

	By:	 	 
	 	Name:  	LOU POSNER	 
	 	Title: 	MANAGING DIRECTOR	 

 

 

2ruby_Ex4_1

		
			Exhibit 4.1
		

		
			DESCRIPTION OF THE REGISTRANT’S SECURITIES 
		

		
			REGISTERED PURSUANT TO SECTION 12 OF THE 
		

		
			SECURITIES EXCHANGE ACT OF 1934 
		

		
			 
		

		
			The summary of the general terms and provisions of the registered securities of Rubius Therapeutics, Inc.  (the “Company,” “we,” “us,” and “our”) set forth below does not purport to be complete. It is subject to and qualified in its entirety by reference to our Amended and Restated Certificate of Incorporation (“Certificate of Incorporation”) and our Amended and Restated Bylaws (“Bylaws”), each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.3 is a part, and by applicable law. We encourage you to read our Certificate of Incorporation, our Bylaws and the applicable provisions of the Delaware General Corporation Law for additional information. 
		

		
			General 
		

		
			Our authorized capital stock consists of 150,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share, all of which shares of preferred stock are undesignated. 
		

		
			Common Stock 
		

		
			Only our common stock is registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
		

		
			The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends, but only when and as declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. 
		

		
			In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. All outstanding shares are fully paid and non-assessable. 
		

		
			Undesignated Preferred Stock 
		

		
			Our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. The purpose of authorizing our board of directors to issue preferred stock in one or more series and determine the number of shares in the series and its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. 
		

		
			The existence of authorized but unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of preferred stock 

		 

to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our Certificate of Incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us.
		

		
			No shares of preferred stock are outstanding as of the date of our Annual Report on Form 10-K with which this Exhibit 4.3 is filed as an exhibit. 
		

		
			Registration Rights
		

		
			Pursuant to the terms of our second amended and restated investors’ rights agreement, dated as of February 23, 2018 (the  “investors’ rights agreement”), certain of our stockholders are entitled to rights with respect to the registration of their shares under the Securities Act of 1933, as amended (the “Securities Act”) until the earliest of (a) the fifth (5th) anniversary of our initial public offering, (b) a deemed liquidation event, as defined in the investors’ rights agreement, or (c) such time as such holder’s registrable securities could be sold without any restriction on volume or manner of sale on any three month period under Rule 144 or any successor rule. We refer to these shares collectively as registrable securities.
		

		
			Demand Registration Rights
		

		
			The holders of 38,296,526 shares of our common stock are entitled to demand registration rights. Under the terms of the investors’ rights agreement, we will be required, upon the written request of the holders of a majority of our outstanding registrable securities then outstanding, as defined in the investors’ rights agreement, that would result in an anticipated aggregate offering price of at least $10.0 million, to file a registration statement and use best efforts to effect the registration of all or a portion of these shares for public resale. We are required to effect only two registrations pursuant to this provision of the investors’ rights agreement.
		

		
			Short-Form Registration Rights
		

		
			Pursuant to the investors’ rights agreement, if we are eligible to file a registration statement on Form S-3, upon the written request of at least 30% of the holders of registrable securities to sell registrable securities at an aggregate offering amount, net of selling expenses, of at least $5.0 million, we will be required to use commercially reasonable efforts to effect a registration of those shares. We are required to effect only two registrations in any 12-month period pursuant to this provision of the investors’ rights agreement. The right to have those shares registered on Form S-3 is further subject to other specified conditions and limitations.
		

		
			Piggyback Registration Rights
		

		
			Pursuant to the investors’ rights agreement, if we register any of our securities either for our own account or for the account of other security holders, the holders of the registrable securities are entitled to include their shares in the registration. Subject to certain exceptions contained in the investors’ rights agreement, we and the underwriters may limit the number of shares included in the underwritten offering to the number of shares which we and the underwriters determine in our sole discretion will not jeopardize the success of the offering.
		

		
			Indemnification
		

		
			Our investors’ rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them.
		

		
			

		 

		

		
			Expiration of Registration Rights
		

		
			The demand registration rights, short form registration rights and piggyback registration rights granted under the investors’ rights agreement will terminate on (a) the fifth anniversary of our initial public offering, (b) a deemed liquidation event, as defined in the investors’ rights agreement, or (c) with respect to any stockholder at such time as such holder’s shares may be sold without restriction pursuant to Rule 144 within a three-month period.
		

		
			Anti-Takeover Effects of our Certificate of Incorporation and Bylaws and Delaware Law 
		

		
			Our Certificate of Incorporation and Bylaws include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue non-negotiated takeover attempts. These provisions include the items described below. 
		

		
			Board Composition and Filling Vacancies 
		

		
			Our Certificate of Incorporation provides for the division of our board of directors into three classes serving staggered three-year terms, with one class being elected each year. Our certificate of incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of two-thirds (2/3) or more of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in office, even if less than a quorum. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of our board of directors. 
		

		
			No Written Consent of Stockholders 
		

		
			Our Certificate of Incorporation provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This requirement may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our Bylaws or removal of directors by our stockholders without holding a meeting of stockholders. 
		

		
			Meetings of Stockholders 
		

		
			Our Certificate of Incorporation and Bylaws provide that only a majority of the members of our board of directors then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our Bylaws limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting. 
		

		
			Advance Notice Requirements 
		

		
			Our Bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Our Bylaws specify the requirements as to form and content of all stockholders’ notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting. 
		

		
			Amendment to Certificate of Incorporation and Bylaws 
		

		
			

		 

		

		
			Any amendment of our Certificate of Incorporation must first be approved by a majority of our board of directors, and if required by law or our Certificate of Incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, board composition, limitation of liability and the amendment of our Bylaws and Certificate of Incorporation must be approved by not less than two-thirds (2/3) of the outstanding shares entitled to vote on the amendment, and not less than two-thirds (2/3) of the outstanding shares of each class entitled to vote thereon as a class. Our Bylaws may be amended by the affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the Bylaws, and may also be amended by the affirmative vote of at least two-thirds (2/3) of the outstanding shares entitled to vote on the amendment, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class. 
		

		
			Undesignated Preferred Stock 
		

		
			Our Certificate of Incorporation provides for 10,000,000 authorized shares of undesignated preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our Certificate of Incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. 
		

		
			Choice of Forum 
		

		
			Our Bylaws provides that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of or based on a breach of a fiduciary duty owed by any of our current or former directors, officers and employees to us or our stockholders, (iii) any action asserting a claim against us or any of our current or former directors, officers, employees or stockholders arising pursuant to any provision of the Delaware General Corporation Law, our Certificate of Incorporation or our Bylaws, (iv) any action to interpret, apply, enforce or determine the validity of our Certificate of Incorporation or our Bylaws, or (v) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein (the “Delaware Forum Provision”). The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our Bylaws further provide that, unless we consent in writing to an alternative forum, the United States District Court for the District of Massachusetts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act (the “Federal Forum Provision”). We have chosen the United States District Court for the District of Massachusetts as the exclusive forum for these causes of action because our principal executive offices are located in Cambridge, Massachusetts. 
		

		
			On December 19, 2018, in Sciabacucchi v. Salzberg, C.A. No. 2017-0931-JTL (Del. Ch.), the Court of Chancery of the State of Delaware issued a decision declaring that federal forum provisions purporting to require claims under the Securities Act be brought in federal court are ineffective and invalid under Delaware law. On January 17, 2019, the decision was appealed to the Delaware Supreme Court. While the Delaware Supreme Court dismissed the initial appeal on jurisdictional grounds, the appeal was re-filed to the Delaware Supreme Court on August 5, 2019 and remains pending. Unless and until the Court of Chancery’s decision is reversed by the Delaware Supreme Court or otherwise abrogated, we do not intend to enforce our Federal Forum Provision designating the District of Massachusetts as the exclusive forum for Securities Act claims. In the event that the Delaware Supreme 

		 

Court affirms the Court of Chancery’s decision or otherwise determines that federal forum selection provisions are invalid, our board of directors intends to amend promptly our Bylaws to remove our Federal Forum Provision. 
		

		
			We recognize that the Federal Forum Provision may impose additional litigation costs on stockholders who assert the provision is not enforceable and may impose more general additional litigation costs in pursuing any these claims, particularly if the stockholders do not reside in or near the State of Delaware or the Commonwealth of Massachusetts. Additionally, the forum selection clauses in our Bylaws may limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us. Alternatively, if the Federal Forum Provision is found inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could have an adverse effect on our business, prospects, financial condition or results of operations. The Court of Chancery of the State of Delaware and the United States District Court for the District of Massachusetts may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. Although we believe this provision benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits against our directors and officers. 
		

		
			Section 203 of the Delaware General Corporation Law 
		

		
			We are subject to the provisions of Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:
		

			
	
			
				 ·
			

			
	
			
			before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;

			
	
			
				 ·
			

			
	
			
			upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or  

			
	
			
				 ·
			

			
	
			
			at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds (2/3) of the outstanding voting stock which is not owned by the interested stockholder.

		
			Section 203 defines a business combination to include:
		

			
	
			
				 ·
			

			
	
			
			any merger or consolidation involving the corporation and the interested stockholder;  

			
	
			
				 ·
			

			
	
			
			any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;   

			
	
			
				 ·
			

			
	
			
			subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;  

			
	
			
				 ·
			

			
	
			
			subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and  

			
	
			
				 ·
			

			
	
			
			the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.

		
			In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. 
		

		
			

		 

		

		
			Nasdaq Global Select Market Listing 
		

		
			Our common stock is listed on The Nasdaq Global Select Market under the symbol “RUBY”. 
		

		
			Transfer Agent and Registrar 
		

		
			The transfer agent and registrar for our common stock is American Stock Transfer & Trust Company, LLC. The transfer agent and registrar’s address is 6201 15th Avenue, Brooklyn, NY 11219 and its telephone number is (800) 937-5449.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]